Compounds > eflornithine
Page last updated: 2024-10-25

eflornithine and Recrudescence

eflornithine has been researched along with Recrudescence in 18 studies

Eflornithine: An inhibitor of ORNITHINE DECARBOXYLASE, the rate limiting enzyme of the polyamine biosynthetic pathway.
eflornithine : A fluoroamino acid that is ornithine substituted by a difluoromethyl group at position 2.

Research Excerpts

ExcerptRelevanceReference
"To evaluate the efficacy and toxicity of a combination of eflornithine and melarsoprol among relapsing cases of Gambian trypanosomiasis."9.10Combination of eflornithine and melarsoprol for melarsoprol-resistant Gambian trypanosomiasis. ( Mpia, B; Pépin, J, 2002)
"To evaluate the efficacy and toxicity of a combination of eflornithine and melarsoprol among relapsing cases of Gambian trypanosomiasis."5.10Combination of eflornithine and melarsoprol for melarsoprol-resistant Gambian trypanosomiasis. ( Mpia, B; Pépin, J, 2002)
"Twenty-two patients with the acquired immune deficiency syndrome (AIDS) and severe debilitating diarrhea caused by Cryptosporidium received eflornithine as therapy."3.67Intestinal crytosporidiosis treated with eflornithine: a prospective study among patients with AIDS. ( Bodey, GP; Fainstein, V; Rolston, KV, 1989)
" This open trial shows that DFMO is as active as and possibly less toxic than melarsoprol."2.67Efficacy and toxicity of eflornithine for treatment of Trypanosoma brucei gambiense sleeping sickness. ( Ethier, L; Loko, L; Milord, F; Mpia, B; Pépin, J, 1992)
"Human African trypanosomiasis, or sleeping sickness, is a painful and protracted disease affecting people in the poorest parts of Africa and is fatal without treatment."2.49Chemotherapy for second-stage human African trypanosomiasis. ( Kennedy, A; Lutje, V; Seixas, J, 2013)
"Human African trypanosomiasis, or sleeping sickness, is a painful and protracted disease affecting people in the poorest parts of Africa and is fatal without treatment."2.46Chemotherapy for second-stage Human African trypanosomiasis. ( Kennedy, A; Lutje, V; Seixas, J, 2010)
"Relapses were noted in 3."2.38Human trypanosomiasis in the Ivory Coast: therapy and problems. ( Doua, F; Yapo, FB, 1993)

Research

Studies (18)

TimeframeStudies, this research(%)All Research%
pre-19904 (22.22)18.7374
1990's5 (27.78)18.2507
2000's3 (16.67)29.6817
2010's6 (33.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Kazumba, LM1
Kaka, JT1
Ngoyi, DM1
Tshala-Katumbay, D1
Chen, N1
Jin, K1
Xu, J1
Zhang, J1
Weng, Y1
Lutje, V2
Seixas, J2
Kennedy, A2
Saulnier Sholler, GL1
Gerner, EW1
Bergendahl, G1
MacArthur, RB1
VanderWerff, A1
Ashikaga, T1
Bond, JP1
Ferguson, W1
Roberts, W1
Wada, RK1
Eslin, D1
Kraveka, JM1
Kaplan, J1
Mitchell, D1
Parikh, NS1
Neville, K1
Sender, L1
Higgins, T1
Kawakita, M1
Hiramatsu, K1
Moriya, SS1
Bachmann, AS1
Truc, P1
Lando, A1
Penchenier, L1
Vatunga, G1
Josenando, T1
Mpia, B2
Pépin, J3
Balasegaram, M1
Harris, S1
Checchi, F1
Hamel, C1
Karunakara, U1
de Gee, AL1
McCann, PP1
Mansfield, JM1
Doua, F2
Boa Yapo, F1
Yapo, FB1
Matovu, E1
Enyaru, JC1
Legros, D1
Schmid, C1
Seebeck, T1
Kaminsky, R1
Blanchot, I1
Dabadie, A1
Tell, G1
Guiguen, C1
Faugère, B1
Plat-Pelle, AM1
Roussey, M1
Milord, F2
Loko, L1
Ethier, L1
Onyeyili, PA1
Onwualu, JE1
Rolston, KV1
Fainstein, V1
Bodey, GP1
Bales, JD1
Harrison, SM1
Mbwabi, DL1
Schecter, PJ1
Guern, C1
Schechter, PJ1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase I Trial for Refractory or Relapsed Neuroblastoma With DFMO Alone and in Combination With Etoposide[NCT01059071]Phase 121 participants (Actual)Interventional2010-02-28Completed
TArgeting Type 1 Diabetes Using POLyamines (TADPOL): A Randomized, Double-Masked, Placebo-Controlled Phase 2 Study to Evaluate the Efficacy and Safety of Difluoromethylornithine (DFMO) to Preserve Insulin Production in Type 1 Diabetes[NCT05594563]Phase 270 participants (Anticipated)Interventional2023-03-14Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

AUC of DFMO in Pediatrics Using Pharmacokinetic (PK) Testing.

(NCT01059071)
Timeframe: Cycle 1 Day 8 at hour 0 (pre-dose), 30 minutes, 1 hour, 3 hours, and 6 hours

Intervention(mcg/ml) * hr (Mean)
DFMO and Etoposide108.38

Cmax of DFMO in Pediatrics Using Pharmacokinetic (PK) Testing.

(NCT01059071)
Timeframe: Cycle 1 Day 8 at hour 0 (pre-dose), 30 minutes, 1 hour, 3 hours, and 6 hours

Interventionmcg/ml (Mean)
DFMO and Etoposide28.89

Number of Participants With Adverse Events as a Measure of Safety and Tolerability

To determine the safety, tolerability and maximum tolerated dose (MTD) of DFMO as a single agent and in combination with etoposide in pediatric and young adult patients with refractory or recurrent neuroblastoma (NCT01059071)
Timeframe: length of study plus 30 days

Interventionparticipants (Number)
Dose Level 1: 500 mg/m2 PO BID2
Dose Level 2: 750 mg/m2 PO BID4
Dose Level 3:1000 mg/m2 PO BID0
Dose Level 4:1500 mg/m2 PO BID5

Number of Patients With an Overall Response Rate (ORR) of PR or CR

Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. (NCT01059071)
Timeframe: 1 year

Interventionparticipants (Number)
DFMO and Etoposide4

Progression Free Survival (PFS)

Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions (NCT01059071)
Timeframe: 2 years

InterventionDays (Median)
DFMO and Etoposide85

Tmax of DFMO in Pediatrics Using Pharmacokinetic (PK) Testing.

(NCT01059071)
Timeframe: Cycle 1 Day 8 at hour 0 (pre-dose), 30 minutes, 1 hour, 3 hours, and 6 hours

Interventionhours (Mean)
DFMO and Etoposide2.88

Reviews

3 reviews available for eflornithine and Recrudescence

ArticleYear
Chemotherapy for second-stage human African trypanosomiasis.
    The Cochrane database of systematic reviews, 2013, Jun-28, Issue:6

    Topics: Animals; Antiprotozoal Agents; Drug Therapy, Combination; Eflornithine; Humans; Melarsoprol; Nifurti

2013
Chemotherapy for second-stage Human African trypanosomiasis.
    The Cochrane database of systematic reviews, 2010, Aug-04, Issue:8

    Topics: Animals; Antiprotozoal Agents; Drug Therapy, Combination; Eflornithine; Humans; Melarsoprol; Nifurti

2010
Human trypanosomiasis in the Ivory Coast: therapy and problems.
    Acta tropica, 1993, Volume: 54, Issue:3-4

    Topics: Animals; Cote d'Ivoire; Eflornithine; Humans; Melarsoprol; Pentamidine; Recurrence; Trypanosoma bruc

1993

Trials

3 trials available for eflornithine and Recrudescence

ArticleYear
A Phase I Trial of DFMO Targeting Polyamine Addiction in Patients with Relapsed/Refractory Neuroblastoma.
    PloS one, 2015, Volume: 10, Issue:5

    Topics: Adolescent; Child; Child, Preschool; Eflornithine; Etoposide; Female; Humans; Infant; Male; Neurobla

2015
Combination of eflornithine and melarsoprol for melarsoprol-resistant Gambian trypanosomiasis.
    Tropical medicine & international health : TM & IH, 2002, Volume: 7, Issue:9

    Topics: Adolescent; Adult; Congo; Drug Administration Schedule; Drug Therapy, Combination; Eflornithine; Fem

2002
Efficacy and toxicity of eflornithine for treatment of Trypanosoma brucei gambiense sleeping sickness.
    Lancet (London, England), 1992, Sep-12, Volume: 340, Issue:8820

    Topics: Administration, Oral; Animals; Cerebrospinal Fluid; Democratic Republic of the Congo; Diarrhea; Eflo

1992

Other Studies

12 other studies available for eflornithine and Recrudescence

ArticleYear
Mortality trends and risk factors in advanced stage-2 Human African Trypanosomiasis: A critical appraisal of 23 years of experience in the Democratic Republic of Congo.
    PLoS neglected tropical diseases, 2018, Volume: 12, Issue:6

    Topics: Adolescent; Adult; Democratic Republic of the Congo; Disease Management; Drug Therapy, Combination;

2018
Human African trypanosomiasis caused by Trypanosoma brucei gambiense: The first case report in China.
    International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2019, Volume: 79

    Topics: Animals; China; Communicable Diseases, Imported; Eflornithine; Fatal Outcome; Gabon; Humans; Male; M

2019
Human African trypanosomiasis in Angola: clinical observations, treatment, and use of PCR for stage determination of early stage of the disease.
    Transactions of the Royal Society of Tropical Medicine and Hygiene, 2012, Volume: 106, Issue:1

    Topics: Adult; Angola; Animals; Eflornithine; Female; Follow-Up Studies; Humans; Lymphocyte Count; Male; Nuc

2012
Treatment outcomes and risk factors for relapse in patients with early-stage human African trypanosomiasis (HAT) in the Republic of the Congo.
    Bulletin of the World Health Organization, 2006, Volume: 84, Issue:10

    Topics: Adolescent; Adult; Animals; Child; Cohort Studies; Democratic Republic of the Congo; Disease Progres

2006
Role of antibody in the elimination of trypanosomes after DL-alpha-difluoromethylornithine chemotherapy.
    The Journal of parasitology, 1983, Volume: 69, Issue:5

    Topics: Animals; Antibodies; Antibody Formation; Antigens, Surface; Cyclophosphamide; Eflornithine; Immunosu

1983
[Current therapy of trypanosomiasis].
    Bulletin de la Societe de pathologie exotique (1990), 1994, Volume: 87, Issue:5

    Topics: Adenosylmethionine Decarboxylase; Animals; Arsenicals; Deoxyadenosines; Drug Resistance; Eflornithin

1994
Melarsoprol refractory T. b. gambiense from Omugo, north-western Uganda.
    Tropical medicine & international health : TM & IH, 2001, Volume: 6, Issue:5

    Topics: Animals; DNA, Protozoan; Drug Resistance; Eflornithine; Humans; Melarsoprol; Microbial Sensitivity T

2001
[Recurrent fever episodes in an African child: diagnostic difficulties of trypanosomiasis in France].
    Pediatrie, 1992, Volume: 47, Issue:3

    Topics: Angola; Child, Preschool; Eflornithine; Fever; France; Humans; Male; Recurrence; Trypanosomiasis, Af

1992
Efficacy of combination of DFMO and diminazene aceturate in the treatment of late stage Trypanosoma brucei brucei infection in rats.
    Tropical medicine and parasitology : official organ of Deutsche Tropenmedizinische Gesellschaft and of Deutsche Gesellschaft fur Technische Zusammenarbeit (GTZ), 1991, Volume: 42, Issue:2

    Topics: Animals; Brain Diseases; Diminazene; Drug Synergism; Drug Therapy, Combination; Eflornithine; Female

1991
Intestinal crytosporidiosis treated with eflornithine: a prospective study among patients with AIDS.
    Journal of acquired immune deficiency syndromes, 1989, Volume: 2, Issue:5

    Topics: Acquired Immunodeficiency Syndrome; Adult; Cryptosporidiosis; Diarrhea; Eflornithine; Female; Humans

1989
Treatment of arsenical refractory Rhodesian sleeping sickness in Kenya.
    Annals of tropical medicine and parasitology, 1989, Volume: 83 Suppl 1

    Topics: Adult; Animals; Arsenicals; Drug Therapy, Combination; Eflornithine; Female; Humans; Kenya; Male; Me

1989
Difluoromethylornithine for arseno-resistant Trypanosoma brucei gambiense sleeping sickness.
    Lancet (London, England), 1987, Dec-19, Volume: 2, Issue:8573

    Topics: Administration, Oral; Adolescent; Animals; Arsenicals; Child; Child, Preschool; Diarrhea; Drug Resis

1987